Google
 
Web globalrph.com
Home back Drug Search Drug Tables disclaimer *Health topics* Professional Resource 

 Phenytoin Dosing Calculator
This document Copyright © 2008  D.McAuley, GlobalRPh Inc. All Rights Reserved.

Patient Name:      Floor:
Age       Weight      Height
Sex      Current albumin level: (g/dl)
What is the current phenytoin level if available? (mcg/ml)
Dosage form used for maintenance dose:
Estimated creatinine clearance:

Read the following:
Disclaimer     -    Program background information

 

1. Allen JP, Ludden TM, Burrow SR, Clementi WA, Stavchansky SA.  Phenytoin cumulation kinetics.
Clin Pharmacol Ther. 1979 Oct;26(4):445-8.
2.  Bachmann KA, Belloto RJ Jr.  Differential kinetics of phenytoin in elderly patients. Drugs Aging. 1999 Sep;15(3):235-50.
3.  Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther. 1982 Mar;31(3):301-4.
4.  Burton ME, Vasko MR, Brater DC.  Comparison of drug dosing methods.   Clin Pharmacokinet. 1985 Jan-Feb;10(1):1-37.

5.  Dager WE, Inciardi JF, Howe TL.  Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia.  Ann Pharmacother. 1995 Jul-Aug;29(7-8):667-70.
6.  Dasgupta A, Dennen DA, Dean R, McLawhon RW. Prediction of free phenytoin levels based on [total phenytoin]/[albumin] ratios. Potential errors with hypoalbuminemia. Am J Clin Pathol. 1991 Feb;95(2):253-6.
7.  Dela Cruz FG, Kanter MZ, Fischer JH, Leikin JB. Efficacy of individualized phenytoin sodium loading doses administered by intravenous infusion. Clin Pharm. 1988 Mar;7(3):219-24.
8.  Flint N, Lopez LM, Robinson JD, Williams C, Salem RB. Related ArticlesComparison of eight phenytoin dosing methods in institutionalized patients.
Ther Drug Monit. 1985;7(1):74-80.
9.  Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, Mullen PW, Wadsworth J, Richens A, Ishizaki T, Chiba K, et al.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data
10.  Gugler R, Manion CV, Azarnoff DL.  Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther. 1976 Feb;19(2):135-42.
11.  Hayes MJ, Langman MJ, Short AH.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.  Br J Clin Pharmacol. 1975 Feb;2(1):73-9.
12.   Hudson SA, Farquhar DL, Thompson D, Smith RG. Phenytoin dosage individualization--five methods compared in the elderly.  J Clin Pharm Ther. 1990 Feb;15(1):25-34.
13.  Liponi DF, Winter ME, Tozer TN.  Renal function and therapeutic concentrations of phenytoin. Neurology. 1984 Mar;34(3):395-7.
14.  Mabuchi H, Nakahashi H.  A major inhibitor of phenytoin binding to serum protein in uremia. Nephron. 1988;48(4): 310-4.
15.  Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm. 1977 Dec;5(6):579-96.
16.  Martin E, Gambertoglio JG, Adler DS, Tozer TN, Roman LA, Grausz H.  Removal of phenytoin by hemodialysis in uremic patients.  JAMA. 1977 Oct 17;238(16):1750-3.
17.  Mason GD, Winter ME.  Appropriateness of sampling times for therapeutic drug monitoring. Am J Hosp Pharm. 1984 Sep;41(9):1796-801.
18.  Mauro LS, Mauro VF, Bachmann KA, Higgins JT.  Accuracy of two equations in determining normalized phenytoin concentrations.  DICP. 1989 Jan;23(1):64-8.
19.  McCauley DL, Tozer TN, Winter ME.  Time for phenytoin concentration to peak: consequences of first-order and zero-order absorption. Ther Drug Monit. 1989 Sep;11(5):540-2.
20.  Mlynarek ME, Peterson EL, Zarowitz BJ.  Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient. Ann Pharmacother. 1996 Mar;30(3): 219-23.
21.  Peterson GM, Khoo BH, von Witt RJ.  Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit. 1991 Sep;13(5):415-9.
22.  Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part I: Phenytoin. Clin Pharmacokinet. 1991 Mar;20(3):209-17.
23.  Sawchuk RJ, Rector TS.  Steady-state plasma concentrations as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: consequences for phenytoin therapy.  J Pharmacokinet Biopharm. 1979 Dec;7(6):543-55.
24.  Sheiner LB, Beal SL.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.  J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71.
25.  Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd Ed. Vancouver, WA: Applied Therapeutics; 1992: 25.1 - 25.44
Contact . Privacy Policy .  Disclaimer

Copyright  © 2005 GlobalRPh Inc.